OneDigital Investment Advisors LLC Sells 1,507 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

OneDigital Investment Advisors LLC reduced its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 22.9% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 5,078 shares of the biotechnology company’s stock after selling 1,507 shares during the period. OneDigital Investment Advisors LLC’s holdings in BioMarin Pharmaceutical were worth $357,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. Primecap Management Co. CA grew its stake in shares of BioMarin Pharmaceutical by 0.4% during the 2nd quarter. Primecap Management Co. CA now owns 18,790,085 shares of the biotechnology company’s stock worth $1,546,988,000 after acquiring an additional 76,190 shares during the period. Avoro Capital Advisors LLC increased its stake in shares of BioMarin Pharmaceutical by 4.4% in the second quarter. Avoro Capital Advisors LLC now owns 4,557,416 shares of the biotechnology company’s stock worth $375,212,000 after purchasing an additional 192,416 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of BioMarin Pharmaceutical by 38.9% in the second quarter. Dimensional Fund Advisors LP now owns 1,034,457 shares of the biotechnology company’s stock valued at $85,178,000 after purchasing an additional 289,953 shares during the period. DNB Asset Management AS lifted its stake in shares of BioMarin Pharmaceutical by 17.7% during the 2nd quarter. DNB Asset Management AS now owns 1,021,054 shares of the biotechnology company’s stock valued at $84,063,000 after buying an additional 153,867 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its holdings in BioMarin Pharmaceutical by 1,858.6% in the 2nd quarter. Principal Financial Group Inc. now owns 649,460 shares of the biotechnology company’s stock worth $53,470,000 after buying an additional 616,301 shares during the period. Hedge funds and other institutional investors own 98.71% of the company’s stock.

Insider Buying and Selling at BioMarin Pharmaceutical

In related news, EVP Charles Greg Guyer sold 5,278 shares of the stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $66.37, for a total value of $350,300.86. Following the completion of the transaction, the executive vice president now directly owns 68,909 shares in the company, valued at $4,573,490.33. This trade represents a 7.11 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.85% of the company’s stock.

BioMarin Pharmaceutical Trading Up 1.4 %

BMRN stock opened at $63.44 on Friday. BioMarin Pharmaceutical Inc. has a one year low of $61.15 and a one year high of $99.56. The company has a market capitalization of $12.09 billion, a PE ratio of 37.99, a price-to-earnings-growth ratio of 0.61 and a beta of 0.31. The company’s 50 day moving average price is $68.67 and its two-hundred day moving average price is $78.60. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.62 and a current ratio of 4.27.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.55 EPS for the quarter, missing analysts’ consensus estimates of $0.78 by ($0.23). The firm had revenue of $746.00 million for the quarter, compared to the consensus estimate of $703.37 million. BioMarin Pharmaceutical had a net margin of 11.71% and a return on equity of 8.53%. The company’s quarterly revenue was up 28.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.26 earnings per share. As a group, analysts predict that BioMarin Pharmaceutical Inc. will post 2.47 earnings per share for the current fiscal year.

Analyst Ratings Changes

BMRN has been the topic of several recent research reports. Evercore ISI dropped their target price on BioMarin Pharmaceutical from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 30th. Robert W. Baird cut their target price on BioMarin Pharmaceutical from $72.00 to $65.00 and set a “neutral” rating for the company in a research note on Wednesday, October 30th. Stifel Nicolaus cut their price target on shares of BioMarin Pharmaceutical from $115.00 to $87.00 and set a “buy” rating for the company in a report on Tuesday, September 17th. UBS Group upped their price target on shares of BioMarin Pharmaceutical from $104.00 to $106.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Finally, Royal Bank of Canada reissued a “sector perform” rating and set a $80.00 price objective on shares of BioMarin Pharmaceutical in a research note on Wednesday, October 30th. Seven equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $94.20.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.